Business
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein
About this update from Ono Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/69d3a816d97dbd34069cdee010c18897"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mtGIl1xO2PAK552vl_aF8w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/69d3a816d97dbd34069cdee010c18897","width":480,"height":252}},"lazy":false},{"type":"text","content":"- Exclusive collaboration and license agreement for povetacicept in these countries -","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"- Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA nephropathy and primary membranous nephropathy -","length":249,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & OSAKA, Japan, June 23, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential being studied for the treatment of immunoglobulin A nephropathy (IgAN), primary membranous nephropathy (pMN) and other B cell-mediated diseases.","length":661,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory and commercial milestone payments and tiered royalties. Ono will utilize its extensive development expertise to help advance Vertex’s clinical trials for povetacicept and will be responsible for obtaining marketing authorizations in Japan and South Korea. Following approval, Ono will be solely responsible for commercializing povetacicept in these regions. The agreement includes povetacicept for both IgAN and pMN, with the potential to add other indications.","length":565,"tagName":"p"},{"type":"text","content":""Ono is a proven leader in Japan and South Korea, ...